NHS cancer jab could mean patients spend hours less in hospital A new injectable form of a key cancer drug could see thousands of NHS patients across the UK spending far less time in hospital.

Keytruda, which is already used to treat multiple cancers, is a type of immunotherapy that helps the body's own immune system attack cancer cells.

Since 2015, NHS patients have received the world's best-selling drug through a drip – or intravenous infusion – which can take more than an hour to administer in hospital.

NHS England says the new injection should cut that procedure to just a couple of minutes, saving patients and staff valuable time.

Shirley Xerxes from St Albans in Hertfordshire was one of the first to receive the jab at the Mount Vernon Cancer Centre near Watford.

The 86-year-old said she was in the chair "for a matter of minutes instead of an hour or more".

"It's made such a difference and gives me more time to live my life, including spending more time gardening. "

About 14,000 cancer patients in England start on a course of Keytruda, also known as pembrolizumab, each year, with most of those likely to be moved over to the injectable version.

The drug can currently be used to treat 14 different types of cancer in the UK, including lung, head and neck, cervical and breast.

In its new form, the treatment will be given every three weeks as a one-minute injection or every six weeks as a two-minute injection, depending on an individual's cancer diagnosis.

It is the third immunotherapy drug of its type that can be given via a jab on the NHS after a new form of another treatment, Opdivo or nivolumab, was introduced in some hospitals last year.

What is immunotherapy? Cancer can hide from the body's own immune system by producing proteins that send a "stop signal" telling our immune cells not to attack. Some scientists describe this as the disease hiding behind an "invisibility cloak". Immunotherapy works by blocking the signal allowing those cancer cells to be more easily recognised and destroyed.

That discovery won two scientists - James Allison and Tasuku Honjo - the Nobel Prize for medicine in 2018.

Keytruda was one of the earliest immunotherapy drugs to be approved, first for skin cancer and later for other forms of the disease.

By most measures it is now the biggest-selling prescription medicine in the world, with global sales of $30bn (£22bn) in 2025.

Until now, hospital pharmacy teams have had to prepare a bag of the drug under sterile conditions which is then given as an infusion into the vein through a cannula.

NHS England's national clinical director for cancer, Prof Peter Johnson, said that switching to a standard, speedy injection would save time and benefit patients. "Managing cancer treatment and regular hospital trips can be really exhausting," he said. "If we can do this in a much shorter period of time, it frees up space in our chemotherapy units and means we can start thinking about giving treatment in the community and away from hospitals. "

NHS England said it could not reveal the cost to the health service - its deal with the US drug company Merck Sharp & Dohme (MSD) is confidential But it's understood it will pay around the same price for both versions of the drug.

Keytruda is already one of the most financially successful medicines of all time with estimated sales of $180bn since its launch over a decade ago.

The patents protecting the original drug are due to expire in 2028 in the US and 2031 in Europe, meaning that rival companies could soon copy it and produce cheaper generic versions

Highlighted sentences link to their corresponding claims. Click any highlighted sentence to jump to its detailed analysis.
Highlight Colors Indicate Claim Quality:
✓ Healthy Claim - No fallacies or contradictions detected
⚠️ Minor Issues - Has contradictions or minor fallacies
🚨 Serious Issues - Multiple contradictions or severe fallacies
Quality Criteria: Claims are evaluated for logical fallacies and contradictions with other news sources. Green highlights indicate healthy claims suitable for reference.
Source